Counterfeit drugs — another global health battlefront

Counterfeit drugs — another global health battlefront.

Governments around the world are considering ways to expand access to health care for people in need. But access is worth little if the care isn’t safe and effective.

How do pharmaceutical companies try to curb the counterfeiting, illegal diversion and theft of medicine, and how do they collaborate and track data on the success of these efforts?

Thomas Kubic, president and CEO of the Pharmaceutical Security Institute, explains in a video interview conducted on the sidelines of the International Federation of Pharmaceutical Manufacturers & Associations’ recent 27th annual gathering in New York.

Click the above video and let us know what you think by leaving a comment below.

Want to learn more? Check out the Healthy Means campaign site and tweet us using #HealthyMeans.

Healthy Means is an online conversation hosted by Devex in partnership with Concern Worldwide, Gavi, GlaxoSmithKline, International Federation of Pharmaceutical Manufacturers & Associations, International Federation of Red Cross and Red Crescent Societies, Johnson & Johnson and the United Nations Population Fund to showcase new ideas and ways we can work together to expand health care and live better lives.

About the author

  • Rolf Rosenkranz

    Rolf Rosenkranz oversees a talented team of in-house journalists, correspondents and guest contributors located around the globe. Since joining Devex in early 2008, Rolf has been instrumental in growing its fledgling news operation into the leading online source for global development news and analysis. Previously, Rolf was managing editor at Inside Health Policy, a subscription-based news service in Washington. He has reported from Africa for the Johannesburg-based Star and its publisher, Independent News & Media, as well as the Westdeutsche Allgemeine Zeitung, a German daily.